{"id":13072,"date":"2023-10-11T10:54:00","date_gmt":"2023-10-11T02:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=13072"},"modified":"2024-11-17T11:01:04","modified_gmt":"2024-11-17T03:01:04","slug":"microport-secures-market-approvals-for-ulys-icds-and-invicta-leads-in-japan","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13072","title":{"rendered":"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan"},"content":{"rendered":"\n<p>Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), has received market approvals for its ULYS implantable cardioverter defibrillators (ICDs) and INVICTA defibrillation electrode leads in Japan. This milestone marks a significant expansion for MicroPort in the Japanese medical device market.<\/p>\n\n\n\n<p><strong>Innovative Technology in ULYS ICDs<\/strong><\/p>\n\n\n\n<p>The ULYS ICD is designed with advanced technology that emphasizes low power consumption and boasts the longest expected service life among current ICD products, projected to last up to eight years. It incorporates the PARAD+ arrhythmia discrimination algorithm, clinically validated to achieve the lowest rate of inappropriate shock defibrillation. Additionally, the ULYS device features an AutoMRI function, allowing it to automatically switch to a specific mode during MRI examinations to ensure patient safety.<\/p>\n\n\n\n<p><strong>INVICTA Leads Enhance Cardiac Care<\/strong><\/p>\n\n\n\n<p>MicroPort&#8217;s INVICTA defibrillation lead continuously transmits electrocardiogram signals from the right ventricle to the defibrillator. In cases of bradycardia or life-threatening ventricular arrhythmias, it works in conjunction with the defibrillator to deliver pacing pulses or shock defibrillation signals as needed. The safety and efficacy of the INVICTA lead have been validated through the Apollo clinical research project, which reported a 100% implantation success rate and a 97.4% complication-free rate at the primary clinical endpoint of three months.<\/p>\n\n\n\n<p><strong>Conclusion: Strengthening MicroPort&#8217;s Position in Cardiac Care<\/strong><\/p>\n\n\n\n<p>The approval of ULYS ICDs and INVICTA leads in Japan is a testament to MicroPort&#8217;s commitment to advancing cardiac care technology. With these innovative products, MicroPort CRM is well-positioned to enhance patient outcomes and expand its footprint in the competitive medical device landscape.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[982,192],"class_list":["post-13072","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-hkg-0853","tag-microport-scientific"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), has received market approvals for its ULYS implantable cardioverter defibrillators (ICDs) and INVICTA defibrillation electrode leads in Japan. This milestone marks a significant expansion for MicroPort in the Japanese medical device market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13072\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13072\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-11T02:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-17T03:01:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13072#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13072\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan\",\"datePublished\":\"2023-10-11T02:54:00+00:00\",\"dateModified\":\"2024-11-17T03:01:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13072\"},\"wordCount\":277,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 0853\",\"MicroPort Scientific\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13072#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13072\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13072\",\"name\":\"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-10-11T02:54:00+00:00\",\"dateModified\":\"2024-11-17T03:01:04+00:00\",\"description\":\"Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), has received market approvals for its ULYS implantable cardioverter defibrillators (ICDs) and INVICTA defibrillation electrode leads in Japan. This milestone marks a significant expansion for MicroPort in the Japanese medical device market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13072#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13072\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13072#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), has received market approvals for its ULYS implantable cardioverter defibrillators (ICDs) and INVICTA defibrillation electrode leads in Japan. This milestone marks a significant expansion for MicroPort in the Japanese medical device market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13072","og_locale":"en_US","og_type":"article","og_title":"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13072","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-10-11T02:54:00+00:00","article_modified_time":"2024-11-17T03:01:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13072#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13072"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan","datePublished":"2023-10-11T02:54:00+00:00","dateModified":"2024-11-17T03:01:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13072"},"wordCount":277,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 0853","MicroPort Scientific"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13072#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13072","url":"https:\/\/flcube.com\/?p=13072","name":"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-10-11T02:54:00+00:00","dateModified":"2024-11-17T03:01:04+00:00","description":"Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), has received market approvals for its ULYS implantable cardioverter defibrillators (ICDs) and INVICTA defibrillation electrode leads in Japan. This milestone marks a significant expansion for MicroPort in the Japanese medical device market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13072#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13072"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13072#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13072"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13072\/revisions"}],"predecessor-version":[{"id":13073,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13072\/revisions\/13073"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}